Table 2.

Review of Previous Studies With Heart Transplant Recipients Who Acquired COVID-19

Authors	Year	Number of Heart Transplant Cases	Data	Conclusions
Case-Control Matched
Chaudhry et al	2020	5 (among other solid organ transplants included)	–47 SOT COVID cases –100 NontransplantCOVID controls –Presenting symptoms –SOT: 55% –Diarrhea Case Fatality Rate: –23% SOT –25% Control	Transplant status by itself does not confer an increased risk for mortality.
Sharma et al	2021	9 (among other solid organ transplants included)	–41 SOT COVID cases –121 Non-Transplant COVID controls Presenting symptoms SOT: –43% Dyspnea –32% Cough –32% Fever Case fatality rates: –17% SOT –13% Control	The case fatality rate was similar between SOT recipients and their matched non-SOT controls with COVID-19.
Nonmatched Observational
Latif et al	2020	28 (6 outpatients, 22 hospitalized)	Presenting symptoms: –83% Fever –91% Dyspnea or Cough –48% Gastrointestinal Case fatality rate: –25% HT	HT recipients displayed a higher case fatality rate than other reported populations.
Bottio et al	2021	47 (9 outpatients, 38 hospitalized)	Presenting symptoms: –81% Fever and hypoxemic respiratory failure Case fatality rate: –29.7% HT –15.4% Quoted general population	HT recipients are vulnerable to COVID-19 infection and display 2-fold higher mortality than the general population.
Case-Series
Li et al	2020	2	Presenting symptoms: –Case 1: Fever, chills, fatigue, poor appetite, diarrhea –Case 2: Fever, fatigue, poor appetite –Both cases survived hospitalization	COVID-19 presentations in heart transplant recipients appear similar to those observed in nontransplant recipients.

HT, heart transplant; SOT, solid organ transplant.